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Background: PKM2 is an attractive target for cancer therapy, however, for many cancer cells, PKM2 knockdown
only leads to a modest impairment of survival and proliferation. It is not known whether PKM2 knockdown rewires
cell signaling pathways in these “PKM2 knockdown resistant” cells, and whether the rewired pathways are needed
for their survival.
Findings: In present study, we investigated the effects of PKM2 knockdown on cellular signaling pathways in
“PKM2 knockdown resistant” cancer cells. We found that knockdown of PKM2 leads to activation of Akt.
Furthermore, we revealed that activation of Akt in PKM2 knockdown cells is a result of glycolysis disruption.
Inhibiton of PI3K-Akt signaling pathway leads to significant growth inhibition and apoptosis in PKM2 knockdown
cells.
Conclusions: Overall, our results indicate that activation of Akt is necessary for the survival of PKM2 knockdown
cells. Combing PKM2 knockdown with PI3K or Akt inhibitors may lead to a better chance to kill tumors. Our
research may provide an unexpected opportunity for the development and implementation of drugs targeting cell
metabolism and aberrant Akt signaling.Findings
H1299 cells are resistant to PKM2 knockdown induced
growth inhibition
To knockdown PKM2, we introduced a PKM2 specific
shRNA into a variety of human cancer cell types. Empty
vector (pLKO.1) served as control. After stable cells
were obtained, we checked whether PKM2 is silenced in
our stable cells by western blot. Taking H1299 cells as
an example, as shown in Figure 1A, PKM2 in H1299 Si-
PKM cells was greatly reduced. Protein dilution experi-
ment showed the knockdown efficiency in Si-PKM cells
is higher than 95% at protein level (Figure 1B); further
quantification with Image J showed the knockdown effi-
ciency is about 98%. Even with such a high knockdown
efficiency, we did not observe significant difference in
the maximal proliferation rate between Si-C cells and Si-
PKM cells (Figure 1C). Morphologically, Si-C cells were
different from Si-PKM. While Si-C cells displayed an* Correspondence: yangjb@lzu.edu.cn
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surface. In marked contrast, Si-PKM cells assumed a
spherical shape (Figure 1D).PKM2 knockdown induces activation of Akt signaling
pathway
To investigate possible changed signaling pathways in
Si-PKM cells,we tested the activation status of PI3K-Akt
signaling pathway, one of the most frequently deregulated
signaling pathways in cancers [1,2]. Akt activation involves
the phosphorylation of two residues: threonine 308
(Thr308) and serine 473 (Ser473). As shown in Figure 2A,
phosphorylated Akt (p-Akt) was significantly increased in
Si-PKM cells, while total Akt was not changed. We quan-
tified p-Akt intensity with Image J, p-Akt level was about
3 folds higher in Si-PKM cells (Figure 2B). Activated Akt
has been shown previously to phosphorylate GSK3β at
Ser9 and TSC2 at Thr1462. Indeed, in Si-PKM cells, phos-
phorylation of GSK3β and TSC2 were also increased
(Figure 2C). Then, we tried anther strategy to knockdown
PKM2 in H1299 cells. Transfection of H1299 cells with
a PKM2 specific siRNA also led to a significant decrease
of PKM2 and an increase of p-Akt (Figure 2D). We also. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 H1299 cells are resistant to PKM2 knockdown induced growth inhibition. (A) Knockdown of PKM2 in Si-PKM cells was confirmed
by Western blot. GAPDH was used as equal loading control. (B) PKM2 knockdown efficiency in Si-PKM cells was higher than 95%. Si-C cell lysate
was diluted to 10% and 5%. PKM2 in different dilutions were analyzed by immunoblotting in compare with Si-PKM cell lysate. (C) Maximal
proliferation rates of Si-C and Si-PKM cells are similar. Si-C and Si-PKM cells were seeded into 6-well plates and cell counts were obtained every
24 h for 4 days. Data are shown as means ± SEM. n = 3 (D) Imaging of Si-C and Si-PKM cells with phase-contrast microscope.
Figure 2 PKM2 knockdown induces activation of Akt. (A) Si-C and Si-PKM cell lysates were analyzed by immunoblotting for phosphorylation
of Akt at Thr308 and Ser473. GAPDH was used to verify equal gel loading. (B) The p-Akt levels were normalized to the loading control and
presented as relative conversion to values in Si-C cells. Data are shown as means ± SEM. n = 3. Statistical analyses were carried out using Student’s
t-test. Significance: *p < 0.05; **p < 0.001. (C) Si-C and Si-PKM cell lysates were analyzed by immunoblotting with antibodies against phospho-TSC2
and phospho-GSK3β. GAPDH was used as an equal loading control. (D) H1299 cells were transfected with 20 nM of scramble siRNA and PKM2-specific
siRNA, respectively. 48 hours after transfection, cells were harvested and analyzed by immunoblotting with the following antibodies: p-Akt, total Akt
and PKM2. GAPDH was used as an equal loading control. Similar results were obtained in three independent experiments. Representative data
are shown.
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phosphorylation, in A549, HCT116 and SW480 cells,
PKM2 knockdown all led to increased Akt phosphoryl-
ation (Additional file 1: Figure S1). In “PKM2 knockdown
sensitive” cells, such as MB-MDA-231 and HepG2 cells,
PKM2 knockdown efficiencies are poor, and in these
cells we did not observed a significant increase in p-Akt
(Additional file 2: Figure S2).
Activation of Akt signaling pathway in PKM2 knockdown
cells is a result of glycolysis disruption
Then, we reconstituted PKM2 and PKM1 in Si-PKM cells,
respectively; we named PKM2 reconstituted Si-PKM cells
PKM2 and PKM1 reconstituted Si-PKM cells PKM1
(Figure 3A). When expression of PKM2 was restored in
Si-PKM cells, p-Akt decreased to a similar level as that
of Si-C cells (Figure 3B). These data clearly show that
up-regulation of p-Akt is a bona fide result of PKM2
knockdown. We also found that PKM1 expression
could normalize p-Akt to a similar level as that of Si-C
cells. PKM1 is a constitutive active isoform of pyruvateFigure 3 Activation of Akt is a result of glycolysis disruption. (A) Usin
of PKM1 or PKM2 in Si-PKM cells. Cell lysates were analyzed by immunoblo
was used as an equal loading control. (B) Re-expression of either PKM2 or
cells, Si-PKM cells, PKM1 cells and PKM2 cells were kept in high glucose DM
immunoblotting with antibodies against p-Akt, total Akt and GAPDH. Similar r
data are shown. (D) The p-Akt levels were normalized to the loading control
glucose DMEM. Data are shown as means ± SEM. n = 3. Statistical analyses we
(E) Si-C cells, Si-PKM cells, PKM1 cells and PKM2 cells were treated with 25 mm
immunoblotting with antibodies against p-Akt, total Akt and GAPDH. Similar r
data are shown.kinase and has not been found to play roles other than
catalyzing PEP to pyruvate [3], so expression of PKM1
could only restore pyruvate kinase activity and glyco-
lysis in the cells. The observation that expression of
PKM1 could decrease p-Akt suggests that up-regulation
of p-Akt in Si-PKM cells is due to glycolysis disruption.
To futher test this hypothesis, we tested the effect of
glucose starvation, a strategy that disrupt glycolysis, on
p-Akt in Si-C and Si-PKM cells. Consistence with previ-
ous studies, glucose starvation for 2 hours led to up-
regulation of p-Akt in Si-C cells [4]. However, p-Akt in
Si-PKM cells stayed unchanged in response to glucose
starvation (Figure 3C and D), indicating that Si-PKM
cells are already in a state that mimics glycolysis dis-
ruption. We also test the effect of 2-DG, a glycolysis
inhibitor, on Akt phosphorylation. Similar to glucose
deprivation, 2-DG treatment also led to increased p-Akt
in Si-C cells but not in Si-PKM cells (Figure 3E). Comb-
ing these evidences, we conclude that activation of Akt
in PKM2 knockdown cells is a result of glycolysis
disruption.g a lentiviral protein expression vector, we reconstituted the expression
tting with the following antibodies: PKM1/2, PKM2 and Flag. GAPDH
PKM1 normalized p-Akt to similar level as that of Si-C cells. (C) Si-C
EM or glucose-null DMEM for 2 hours, cell lysates were analyzed by
esults were obtained in three independent experiments. Representative
and presented as relative conversion to values in Si-C cells with high
re carried out using Student’s t-test. Significance: *p < 0.05; **p < 0.001.
ol/L 2-DG or left untreated for 2 hours, cell lysates were analyzed by
esults were obtained in three independent experiments. Representative
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inhibition and cell death in Si-PKM cells
Because Akt activation promotes cell survival, prolifera-
tion and inhibits apoptosis, up-regulation of p-Akt may
be necessary for the survival of PKM2 knockdown cells.
To investigate this possibility, we first evaluated sensi-
tivity of p-Akt to different metabolic and signaling path-
way inhibitors in Si-PKM cells. As shown in Figure 4A,
both PI3K inhibitor wortamannin and autophagy inhibitor
3-MA could inhibit phosphorylation of Akt in Si-PKM
cells, suggesting that phosphorylation of Akt in Si-PKM
cells is through the canonical PI3K-Akt signaling pathway
and is maintained by autophagy. Then we performed a
growth inhibition assay with another PI3K inhibitor
LY294002, whose half-life is much longer than Worta-
mannin. LY294002 was sufficient to block Akt activation
in both Si-C and Si-PKM cells (Figure 4B). After 24 hours
of treatment, LY294002 led to a 60% growth inhibition in
Si-PKM cells; whereas the inhibitory effect in Si-C cells
was much less significant. (Figure 4C). Consistent with
this, cleaved PARP, a marker of apoptosis, significantly
increased in LY294002 treated Si-PKM cells but not in
Si-C cells (Figure 4D). Thus, PKM2 knockdown cells
rely on PI3K-Akt signaling pathway for survival and
proliferation.Figure 4 Inhibition of PI3K-Akt signaling pathway induces growth inh
were treated with: DMSO, 1 μM Wortmannin, 1 μM AKTi, 100 nM Rapamyc
analyzed by Western blot with antibodies against p-Akt and total Akt. GAPD
were treated with 10 μM LY294002 for 24 hours or left untreated, Cell lysat
total Akt, GAPDH was used as an equal loading control. (C) Si-C and Si-PKM
untreated, plates were subjected to MTT assay after 24 h. Reactions were c
analyses were carried out using Student’s t-test. Significance: *p < 0.05; **p
10 μM LY294002 for 24 hours or left untreated, cell lysates were analyzed b
equal loading control. Similar results were obtained in three independent eDiscussion
Pyruvate kinase, especially PKM2, has been shown to
play an important role in the reprogramming and mainten-
ance of altered metabolism in cancer cells [5]. In addition
to metabolic reprogramming, PKM2 has also been demon-
strated to directly regulate gene expression and subsequent
cell cycle progression [6]. At the same time, many onco-
genic signaling pathways promote the metabolic repro-
gramming of cancer cells. It is now well accepted that
systems-level cross-talk between metabolism and signaling
pathways is required in the maintenance of cancer cell
homeostasis [7].
Akt is a positive regulator of PKM2. Akt activation
leads to activation of mTOR1 through phosphorylation
and inhibition of TSC2; mTOR activation induces HIF1α
expression, and HIF1α in turn enhances PKM2 expres-
sion through collaboration with c-Myc–hnRNPs splicing
regulators [8]. Here we show that loss of PKM2 leads to
activation of Akt signaling pathway. Activation of Akt sig-
naling pathway in PKM2 knockdown cells is a result of
glycolysis disruption, and is through the canonical PI3K-
Akt signaling pathway.
Activation of Akt plays important roles in cancer re-
sistance to different therapeutics [9]. Here we show that
resistance of cancer cells to PKM2 deprivation mediatedibition and cell death in Si-PKM cells. (A) Si-PKM cells in 6-well dish
in and 5 mM 3-MA respectively for 2 hours. Cell lysates were then
H was used as an equal loading control. (B) Si-C and Si-PKM cells
es were analyzed by Western blot with antibodies against p-Akt and
cells in 96-well plate were treated with 10 μM LY294002 or left
arried out in triples. Data are shown as means ± SEM. n = 3. Statistical
< 0.001. (D) Si-C and Si-PKM cells in 6 well plate were treated with
y Western blot with antibodies against PARP. GAPDH was used as an
xperiments. Representative data are shown.
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PI3K inhibitor suppress proliferation of PKM2 knock-
down H1299 cells and induces apoptosis. PKM2 knock-
down renders cancer cells exquisitely sensitive to Akt
inhibition. This indicates PKM2 knockdown cells relies
on p-Akt for their survival and proliferation.
In conclusion, we have established a potential role of
PI3K-Akt signaling pathway for survival of PKM2 knock-
down cancer cells. Combining PKM2 knockdown with
Akt or PI3K inhibitor leads to a better chance to kill can-
cer cells. Thus, cancer signaling pathways should be taken
into account when targeting metabolic pathways in treat-
ing cancers.
Additional files
Additional file 1: Figure S1. PKM2 knockdown led to increased p-Akt
in A549, SW480 and HCT116 cells. Cell lysates from Si-C and Si-PKM cells
were analyzed by immunoblotting for p-Akt, total Akt and PKM2. GAPDH
served as an equal loading control.
Additional file 2: Figure S2. PKM2 knockdown didn’t cause p-Akt
up-regulation in MB-MDA-231 and HepG2 cells. Cell lysates from Si-C and
Si-PKM cells were analyzed by immunoblotting with antibodies against
p-Akt, total Akt and PKM2. GAPDH served as an equal loading control.
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